American Foundation Biological

Sequella Inc. is a clinical-stage pharmaceutical company based in Rockville, MD, focused on developing innovative antibiotics to combat drug-resistant bacterial, fungal, and parasitic infections. Their product pipeline addresses significant global health threats, particularly tuberculosis and its multidrug-resistant forms, which impact billions of people worldwide. With two drug candidates having completed phase 2 clinical trials and additional candidates in preclinical development, Sequella aims to tackle various infectious diseases, including Helicobacter pylori infections and Clostridium difficile. Their research also explores treatments for non-tuberculous mycobacterial infections and parasitic diseases, demonstrating a commitment to addressing critical health challenges globally. Generated from the website

Rintech Inc, located in Gaithersburg, MD, specializes in custom synthesis and contract research manufacturing, offering a wide range of chemical and pharmaceutical products. With a commitment to high-quality service, the company collaborates with associated manufacturers in China to meet diverse production needs across various industries. Their offerings include pharmaceutical intermediates, unnatural amino acids, and specialty chemicals, with capabilities to handle quantities from grams to tons. Rintech's team of PhDs and technicians is dedicated to providing tailored solutions for clients, focusing on synthetic method development and drug discovery. Generated from the website

GlycoMimetics is a late clinical-stage biotechnology company based in Gaithersburg, MD, specializing in the discovery and development of glycobiology-based therapies for cancers and inflammatory diseases. Their lead candidate, uproleselan, is currently in pivotal Phase 3 development for relapsed refractory acute myeloid leukemia (AML) and in a Phase 2/3 trial for newly diagnosed AML patients fit for chemotherapy. Uproleselan has received Breakthrough Therapy and Fast Track designations from the U.S. FDA for the treatment of adult AML patients with relapsed or refractory disease. As a pioneer in glycobiology, GlycoMimetics utilizes their proprietary chemistry platform and extensive understanding of the role carbohydrates play in cell recognition to discover innovative medicines that aim to improve patient outcomes. The company has established significant collaborations with leading academics, governmental organizations, and pharmaceutical biotechnology companies to drive their proprietary programs forward.Generated from the website